Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(2 years from now) | |
US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) |
Rezdiffra is owned by Madrigal.
Rezdiffra contains Resmetirom.
Rezdiffra has a total of 4 drug patents out of which 0 drug patents have expired.
Rezdiffra was authorised for market use on 14 March, 2024.
Rezdiffra is available in tablet;oral dosage forms.
Rezdiffra can be used as treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis).
Drug patent challenges can be filed against Rezdiffra from 14 March, 2028.
The generics of Rezdiffra are possible to be released after 17 September, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET;ORAL